Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery · 2026
The Septoplasty Healthcare Monitor: An Outcome Assessment Infrastructure to Enhance the Quality and Transparency of Care.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
van Dam Victor S, Berzenji Diako, van Zijl Floris V W J, Oude Voshaar Martijn A H, Kremer Bernd, Datema Frank R
Аннотация
OBJECTIVE AND DESIGN: The growing demand for transparency about the efficacy of healthcare has accelerated the use of Patient-Reported Outcome Measures (PROMs), but their integration into daily practice is challenging. This observational study describes how the Septoplasty Healthcare Monitor (SHM) addresses these challenges and highlights the benefits of standardised outcome assessments and visualisation for various stakeholders, including physicians and patients.
MAIN OUTCOME MEASURES: Since 2014, all eligible septoplasty patients have been included in the SHM. Patients are automatically offered the Nasal Obstruction Symptom Evaluation (NOSE) scale and bilateral Visual Analogue Scales (VAS) to assess nasal obstruction before initial consultation and during postoperative visits. Data are entered into a preformatted database and automatically analysed. Real-time results are visually presented on a user-friendly dashboard.
RESULTS: A total of 173 patients participated. First, the dashboard provides insights into outcomes on a cohort level. The mean NOSE scores significantly decreased from 68.8 ± 19.0 at baseline to 19.8 ± 22.3 at 12 months (Cohen's d = -1.96). VAS scores improved from 4.6 ± 3.0 (left) and 4.7 ± 2.9 (right) preoperatively to 7.5 ± 2.1 (left) and 7.6 ± 1.7 (right) at 12 months (p < 0.001; d = 0.85; d = 1.05). Second, quality of care is monitored through annual performance metrics and can be improved by critically appraising auto-identified underperforming patients. Third, visualisation of individual PROM symptom-severity scores in relation to peers assists in patient-counselling and shared decision-making.
CONCLUSION: The integration of standardised outcome assessments into daily practice is highly valuable but challenging. The SHM addresses these challenges and offers opportunities to enhance septoplasty care standards.
MAIN OUTCOME MEASURES: Since 2014, all eligible septoplasty patients have been included in the SHM. Patients are automatically offered the Nasal Obstruction Symptom Evaluation (NOSE) scale and bilateral Visual Analogue Scales (VAS) to assess nasal obstruction before initial consultation and during postoperative visits. Data are entered into a preformatted database and automatically analysed. Real-time results are visually presented on a user-friendly dashboard.
RESULTS: A total of 173 patients participated. First, the dashboard provides insights into outcomes on a cohort level. The mean NOSE scores significantly decreased from 68.8 ± 19.0 at baseline to 19.8 ± 22.3 at 12 months (Cohen's d = -1.96). VAS scores improved from 4.6 ± 3.0 (left) and 4.7 ± 2.9 (right) preoperatively to 7.5 ± 2.1 (left) and 7.6 ± 1.7 (right) at 12 months (p < 0.001; d = 0.85; d = 1.05). Second, quality of care is monitored through annual performance metrics and can be improved by critically appraising auto-identified underperforming patients. Third, visualisation of individual PROM symptom-severity scores in relation to peers assists in patient-counselling and shared decision-making.
CONCLUSION: The integration of standardised outcome assessments into daily practice is highly valuable but challenging. The SHM addresses these challenges and offers opportunities to enhance septoplasty care standards.